Abstract
Malignant melanomas are aggressive tumors that are largely refractory to conventional drug therapies. A recent study reported in Nature Genetics identified mutationally activated ErbB4 alleles in 20% of cases. These tumor cells exhibit ErbB4 dependency, suggesting that ErbB4 kinase inhibition may constitute an effective therapeutic strategy in this setting.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Dose-Response Relationship, Drug
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics*
-
ErbB Receptors / metabolism
-
Gene Expression Regulation, Neoplastic
-
Genotype
-
Humans
-
Melanoma / drug therapy
-
Melanoma / genetics*
-
Melanoma / metabolism
-
Melanoma / pathology
-
Mutation
-
Phenotype
-
Protein Kinase Inhibitors / pharmacology
-
Receptor, ErbB-4
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / genetics*
-
Skin Neoplasms / metabolism
-
Skin Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
ERBB4 protein, human
-
ErbB Receptors
-
Receptor, ErbB-4